Literature DB >> 19104791

Clinical pharmacokinetics of aminoglycosides in the neonate: a review.

Gian Maria Pacifici1.   

Abstract

BACKGROUND: Sepsis is common in neonates and is a major cause of morbidity and mortality. Sixty percent of preterm neonates receive at least one antibiotic, and 43% of the antibiotics administered to these neonates are aminoglycosides. The clearance (Cl), serum half-life (t(1/2)), and volume of distribution (Vd) of aminoglycosides change during the neonatal life, and the pharmacokinetics of aminoglycosides need to be studied in neonates in order to optimise therapy with these drugs.
OBJECTIVE: The aim of this work is to review the published data on the pharmacokinetics of aminoglycosides in order to provide a critical analysis of the literature that can be a useful tool in the hands of physicians.
METHODS: The bibliographic search was performed electronically using PubMed, as the search engine, through July 11th, 2008. Firstly, a Medline search was performed with the keywords "pharmacokinetics of aminoglycosides in neonates" with the limit of "human". Other Medline searches were performed with the keywords "pharmacokinetics of ... in neonates" followed by the name of the aminoglycosides: amikacin, gentamicin, netilmicin and tobramycin. In addition, the book Neofax: A Manual of Drugs Used in Neonatal Care by Young and Mangum (Thomson Healthcare, 2007) was consulted.
RESULTS: The aminoglycosides are mainly eliminated by the kidney, and their elimination rates are reduced at birth. As a consequence Cl is reduced and t(1/2) is prolonged in the neonate as compared to more mature infants. The high body-water content of the neonate results in a large Vd of aminoglycosides as these drugs are fairly water soluble. Postnatal development is an important factor in the maturation of the neonate, and as postnatal age proceeds, Cl of aminoglycosides increases.
CONCLUSION: The maturation of the kidney governs the pharmacokinetics of aminoglycosides in the infant. Cl and t(1/2) are influenced by development, and this must be taken into consideration when planning a dosage regimen with aminoglycosides in the neonate. Aminoglycosides are fairly water soluble, and the larger water content of neonates yields a larger Vd in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104791     DOI: 10.1007/s00228-008-0599-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  61 in total

1.  Once daily gentamicin dosing in neonates.

Authors:  C de Alba Romero; E Gómez Castillo; C Manzanares Secades; J Rodriguez López; L Arreaza López; P Saenz Valiente
Journal:  Pediatr Infect Dis J       Date:  1998-12       Impact factor: 2.129

2.  The need for a loading dose of gentamicin in neonates.

Authors:  K L Watterberg; H W Kelly; P Angelus; C Backstrom
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

3.  Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g.

Authors:  Ghanshyam Agarwal; Alok Rastogi; Suma Pyati; Angela Wilks; Rosita S Pildes
Journal:  J Perinatol       Date:  2002-06       Impact factor: 2.521

4.  Comparison of two gentamicin dosing schedules in very low birth weight infants.

Authors:  Alok Rastogi; Ghanshyam Agarwal; Suma Pyati; Rosita S Pildes
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

5.  Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age.

Authors:  Jens Rengelshausen; Bernd Beedgen; Konstantina Tsamouranis; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli; Otwin Linderkamp
Journal:  Eur J Clin Pharmacol       Date:  2006-07-25       Impact factor: 2.953

Review 6.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

7.  A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates.

Authors:  Robert DiCenzo; Alan Forrest; Judianne C Slish; Carol Cole; Ronnie Guillet
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

8.  Clinical pharmacology of netilmicin in preterm and term newborn infants.

Authors:  B Granati; B M Assael; M Chung; C Montini; R Parini; P Pollazzon; L Gagliardi; E Radwanski; F F Rubaltelli
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

9.  Determination of extended-interval gentamicin dosing for neonatal patients in developing countries.

Authors:  Gary L Darmstadt; M Monir Hossain; Atanu Kumar Jana; Samir K Saha; Yoonjoung Choi; S Sridhar; Niranjan Thomas; Mary Miller-Bell; David Edwards; Jacob Aranda; Jeffrey Willis; Patricia Coffey
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

10.  Tobramycin pharmacokinetics in very low birth weight infants.

Authors:  M C Nahata; D A Powell; D E Durrell; M A Miller
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

View more
  24 in total

1.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 2.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  Shripada C Rao; Ravisha Srinivasjois; Kwi Moon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

3.  Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.

Authors:  Aline Fuchs; Monia Guidi; Eric Giannoni; Dominique Werner; Thierry Buclin; Nicolas Widmer; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

4.  Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria.

Authors:  Yuma A Bijleveld; Maria E van den Heuvel; Caspar J Hodiamont; Ron A A Mathôt; Timo R de Haan
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Should gentamicin trough levels be routinely obtained in term neonates?

Authors:  J Ibrahim; D Maffei; G El-Chaar; S Islam; S Ponnaiya; A Nayak; W Rosenfeld; N Hanna
Journal:  J Perinatol       Date:  2016-08-18       Impact factor: 2.521

6.  Designer aminoglycosides prevent cochlear hair cell loss and hearing loss.

Authors:  Markus E Huth; Kyu-Hee Han; Kayvon Sotoudeh; Yi-Ju Hsieh; Thomas Effertz; Andrew A Vu; Sarah Verhoeven; Michael H Hsieh; Robert Greenhouse; Alan G Cheng; Anthony J Ricci
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

7.  Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.

Authors:  Sílvia M Illamola; Helena Colom; J G Coen van Hasselt
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

8.  High-dose gentamicin in newborn infants: is it safe?

Authors:  Jon Widding Fjalstad; Einar Laukli; John N van den Anker; Claus Klingenberg
Journal:  Eur J Pediatr       Date:  2013-11-14       Impact factor: 3.183

9.  Impact of gestational age and birth weight on amikacin clearance on day 1 of life.

Authors:  Michiel F Schreuder; Abraham J Wilhelm; Arend Bökenkamp; Simone M H Timmermans; Henriette A Delemarre-van de Waal; Joanna A E van Wijk
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 8.237

10.  Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia.

Authors:  Adam Frymoyer; Lina Meng; Sonia L Bonifacio; Davide Verotta; B Joseph Guglielmo
Journal:  Pharmacotherapy       Date:  2013-04-01       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.